Subsense develops NanoBCI using intranasal nanoparticles for neurological disorders
AI Summary- Subsense is developing NanoBCI, a non-surgical interface using intranasally delivered nanoparticles.
- $27 million had been raised by Subsense in seed funding as of December 2025.
- Mouse proof-of-concept studies began in late 2025 and are expected to finish by late 2026.